NAD+

What NAD+ is

NAD+ is a molecule that every living cell holds and needs. Scientists have studied it for more than 100 years, first in cells and animals and now in human trials. Those human trials are mostly small, with 20 to 80 people, and short, at 6 to 12 weeks.

The evidence, as of April 2026, is truly mixed. It is strong in animals. A growing number of human trials back it for certain markers in the blood and body. It is far from settled on whether raising NAD+ can lengthen life or prevent disease in people.

The full name is nicotinamide adenine dinucleotide. NAD+ is a coenzyme, a helper molecule that enzymes need to do their work. It is not a peptide, a hormone or a drug. Few molecules in a person’s body are more plentiful. Life depends on it. If NAD+ were gone, a cell would stop making energy within seconds and die.

The history is long:

• 1906. William John Young and Arthur Harden found NAD+ while studying fermentation.
• 1936. Otto Warburg showed what it does in redox reactions. In these reactions, electrons pass from one molecule to another. He found that the nicotinamide part of the molecule is where this happens.
• Early 2000s. NAD+ became a main topic in aging research. Leonard Guarente’s lab had found that sirtuins need NAD+ as a co-substrate, a material they use up as they work. Sirtuins are an enzyme family tied to long life [7].

Most research guides cover peptides and small-molecule drugs. NAD+ is different. It is a natural metabolite, and the body makes and recycles it all the time.

Longevity researchers care about it for one well-recorded reason. NAD+ drops a lot with age, in many tissues and many species. That drop has been tied to weaker mitochondria, a buildup of DNA damage, long-term inflammation and poor metabolism. Together these make up several of the hallmarks of aging [8].

The main question is whether bringing NAD+ back up can slow, stop or reverse the loss of function that comes with age. There are two ways to try. One is to give NAD+ directly. The other is to give a precursor, a smaller molecule the body turns into NAD+. The best-known precursors are NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside).

How much research there is

NAD+ holds an unusual place in longevity science. Its biology is mapped in great detail. The animal evidence is large. Real human trial data exist, which is not true of many compounds in guides like this. Big gaps remain all the same.

Question	Answer
Basic biology	Very firmly established. Its chemistry has more than 100 years of study behind it
Drop with age	Confirmed in many species and tissues. The cause has been identified: CD38 and overactive PARP enzymes
Lifespan in animals	Yeast and worms lived longer. Mouse results are mixed: healthspan got better every time, but the effect on maximum lifespan varied
Human trials of precursors	Several randomized controlled trials of NMN and NR. Most are small (20 to 80 people) and short (6 to 12 weeks)
Human marker evidence	Higher blood NAD+ is confirmed. Better insulin sensitivity was shown with NMN. Blood pressure signals were seen with NR
Lifespan in people	No data. Not one trial has tracked how long people live
Long-term safety	Missing. Most human trials last 6 to 12 weeks. There is no data covering several years
Checked by other labs	Good for the basic biology. Growing for the precursor trials
Approval	No NAD+-related compound is approved as a treatment for aging

This is why the evidence rating is “Mixed”. The base science is solid, and there is more human data than most longevity compounds have. But the key question has no answer yet. Nobody knows if restoring NAD+ adds meaningful healthy years to a human life.

How it works

NAD+ takes part in hundreds of enzyme reactions all through the cell. Its jobs fall into two broad groups. In the first, it is a redox cofactor that ferries electrons between metabolic reactions. In the second, signaling enzymes use it up as a raw material. Both groups help explain why running low on NAD+ has such wide effects.

Making energy

The most basic job of NAD+ is to carry electrons. Cells break down fatty acids, amino acids and glucose for fuel. As they do, NAD+ picks up electrons and becomes NADH, its “reduced” form. This happens mainly in two pathways:

• Glycolysis. NAD+ turns into NADH at the step where glyceraldehyde-3-phosphate becomes 1,3-bisphosphoglycerate.
• The Krebs cycle, also known as the TCA cycle. Inside the mitochondrial matrix, NAD+ picks up electrons at three steps. The NADH that forms later hands them to Complex I, the first stop on the electron transport chain.

The electron transport chain (ETC) is a row of protein complexes in the inner membrane of the mitochondrion. NADH brings electrons to it. Their energy pumps protons across that membrane. This builds up an electrochemical gradient, and the gradient powers an enzyme called ATP synthase. The whole process is named oxidative phosphorylation. It makes about 90% of a cell’s ATP, the molecule cells spend as energy.

NAD+ is rate-limiting here, meaning its supply sets the pace. When NAD+ runs low, the NAD+/NADH ratio drops, and mitochondria make energy less efficiently in step with it [11].

This is more than theory. Muscle samples taken from older adults show the same thing again and again: less NAD+, together with mitochondria that work poorly. And in several studies of old animals, raising NAD+ back up improved exercise capacity and mitochondrial respiration [9].

Sirtuins and gene control

There are seven sirtuins, SIRT1 to SIRT7. They are deacetylases and deacylases that depend on NAD+. In plain terms, they strip small chemical tags off proteins. Through this they regulate gene activity, metabolic balance, DNA repair and inflammation. People sometimes call them “longevity genes”. That label rests on firmer ground in mice, worms and yeast than it does in humans.

The key point is that every sirtuin reaction uses up NAD+. A sirtuin takes an acetyl group off its target protein. A histone or a transcription factor is a typical target. In doing so it splits one NAD+ molecule into nicotinamide and O-acetyl-ADP-ribose. So sirtuin activity is tied directly to the NAD+ supply. Less NAD+ means less sirtuin activity [7].

Each sirtuin works in its own part of the cell and has its own jobs:

• SIRT1 (nucleus and cytoplasm). It removes acetyl groups from p53, PGC-1α, NF-κB and the FOXO transcription factors. It helps build new mitochondria, holds down inflammation and raises resistance to stress.
• SIRT2 (cytoplasm). It regulates the cell cycle, the deacetylation of tubulin and the maturing of fat cells.
• SIRT3 (mitochondria). It is the main deacetylase in mitochondria. It regulates the urea cycle, fatty acid oxidation and oxidative phosphorylation. A fall in SIRT3 activity is directly linked to the mitochondrial problems of aging [1].
• SIRT4 and SIRT5 (mitochondria). They regulate fatty acid oxidation, the metabolism of amino acids, and two tagging processes, succinylation and malonylation.
• SIRT6 (nucleus). It is critical for a stable genome, for telomere upkeep and for base excision repair, one kind of DNA repair. Male mice made to produce extra SIRT6 lived longer.
• SIRT7 (nucleolus). It regulates the copying of ribosomal RNA and the cell’s stress response.

DNA repair and PARP enzymes

PARPs are poly(ADP-ribose) polymerases. This enzyme family finds breaks in one strand of DNA and starts the repair. PARP-1 is the most common member. When it finds a break, it builds chains of poly(ADP-ribose), and NAD+ is the raw material. One NAD+ molecule is needed for each ADP-ribose unit. At a single damage site, PARP-1 can attach chains 200 or more units long.

This sets up a problem in aging. DNA damage piles up over the years. It comes from oxidative stress, copying errors and outside factors. PARP activity rises to match and uses more and more NAD+. The loss of NAD+ then weakens sirtuins and mitochondria. The loop feeds itself, and some call it the “NAD+ drain” [9].

During a DNA damage response, nothing inside the cell uses more NAD+ than PARP-1. Under severe stress to the genome, PARP-1 can become overactive and empty the cell’s NAD+ stores within minutes. Energy production then collapses and the cell dies. This form of cell death is called parthanatos. It works differently from apoptosis.

CD38 and the drop with age

CD38 is a glycoprotein that spans the cell membrane. It has NADase activity. That means it breaks NAD+ down directly, into nicotinamide and cyclic ADP-ribose (cADPR). It was first known as a marker found on cells of the immune system. Today it ranks among the most important controls on NAD+ levels in living animals.

In 2016, a landmark study from Camacho-Pereira and colleagues showed that CD38 is the main driver of the age-related drop [1]:

• Normal (wild-type) mice aged 32 months had about half the NAD+ of young mice.
• Mice of the same age that lacked the CD38 gene showed no drop at all.
• CD38 rises with age, and the rise depends on inflammation.

The study described a loop. Chronic low-grade inflammation, sometimes called inflammaging, pushes CD38 up. CD38 drains NAD+. Low NAD+ harms mitochondria. Damaged mitochondria cause more inflammation.

CD38 also breaks down NMN inside the body. So high CD38 can cancel part of the benefit of taking NMN. This has drawn research interest in pairing a precursor with a CD38 inhibitor, for example apigenin or quercetin. No clinical evidence backs that approach so far [6].

Redox balance and oxidative stress

The NAD+/NADH ratio does more than drive energy production. It also works as a redox sensor for the cell.

• A high ratio signals an oxidized state that is short on energy. It switches on backup pathways. AMPK (AMP-activated protein kinase) is one, and sirtuin signaling is another.
• A low ratio signals a reduced state with plenty of energy.

A related molecule is NADP+, or nicotinamide adenine dinucleotide phosphate. Enzymes called NAD kinases make it from NAD+. It is the main substrate for two enzymes, glutathione reductase and thioredoxin reductase. These are the cell’s two chief antioxidant defense systems. NADPH, the reduced form, supplies the electrons that rebuild reduced glutathione (GSH), the cell’s main antioxidant.

So a shortage of NAD+ also lowers antioxidant capacity further down the line. That ties the fall in NAD+ to the rise in oxidative damage seen in aging.

What the studies found

NAD+ research covers animal and cell models and a growing number of human trials. Both kinds appear below. One caution matters. Most of the data on lifespan and on changing the course of disease comes from animals. Human studies have mostly measured markers, physical performance and safety.

Aging and lifespan

This is the most heavily studied part of the field.

• NAD+ falls with age. Studies in yeast, worms, mice, rats and humans have confirmed it. Key tissues affected include skeletal muscle, liver, brain and fat. At 24 months, mouse tissue NAD+ is typically 30 to 50% below its level at 3 months [1].
• Longer life in simple organisms. Scientists have boosted NAD+ with precursors or by making cells overproduce the enzymes that build it. These methods lengthened life in the worm C. elegans and the yeast Saccharomyces cerevisiae. Mouse results are less simple. NMN improved markers of healthspan, namely bone density, eye function, insulin sensitivity and exercise capacity. It did not reliably extend maximum lifespan [9].
• Healthspan versus lifespan. A broad 2025 review found that changing NAD+ in aging rodents reliably improves measures of function: mitochondrial respiration, physical endurance and glucose balance. This held even where the effect on maximum lifespan was modest or uneven [11].
• People. No human study has used lifespan as its primary endpoint. For now, what precursors have shown in human aging stops at better markers and better function. The metabolic health section and the research table above cover it.

Brain disease

In animal and cell models, low NAD+ has been seen in brain tissue across several neurodegenerative conditions, diseases in which nerve cells break down.

• Alzheimer’s disease. In 2018, Hou and colleagues used a transgenic mouse model that also had a DNA repair defect added. Giving NAD+ brought key Alzheimer’s features back to normal. The ability to repair DNA returned. Brain inflammation fell, with less NLRP3 inflammasome activation. Neurotransmitter levels returned to normal. Treated mice also did better on tests of learning and memory [5].
• Parkinson’s disease. In preclinical studies, restoring NAD+ shielded dopamine-producing neurons from damage by mitochondrial toxins. Turning on SIRT1 and SIRT3 through NAD+ is the proposed protective mechanism. Direct evidence in Parkinson’s models is thinner than for Alzheimer’s.
• Brain inflammation in general. NAD+ turns on sirtuins, SIRT1 above all, and this suppresses inflammatory cascades in the brain that are driven by NF-κB. Scientists find this interesting because chronic brain inflammation is involved in several neurodegenerative conditions.

Not one clinical trial in people has shown that NAD+ supplements help in a neurodegenerative disease of any kind. The animal data are encouraging but have not been confirmed in people.

Metabolic health

This is where NAD+ precursors have their strongest human evidence.

• Insulin sensitivity with NMN. Yoshino and colleagues (2021) ran a 10-week randomized, placebo-controlled trial. The subjects were postmenopausal women with prediabetes. Taking 250 mg of NMN a day raised insulin-stimulated glucose disposal. The team measured this with the hyperinsulinemic-euglycemic clamp, the gold standard method. Insulin signaling in skeletal muscle also went up, seen as AKT and mTOR phosphorylation. Whole-blood NAD+ did not change, which suggests the effects were specific to certain tissues [2].
• Blood NAD+ with NMN. The Uthever trial (Huang and colleagues, 2022) was a multicenter randomized controlled trial in adults aged 40 to 65. They took 300 mg of NMN twice a day for 60 days. Blood NAD+ rose, and physical performance improved on the 6-minute walk test [4].
• Blood NAD+ with NR. In 2018, Martens and colleagues gave 1000 mg of NR a day to healthy adults aged 55 to 79. Blood NAD+ rose by about 60%. There were early signs of lower blood pressure and less stiff arteries [3].
• Obesity and body fat. In models of obesity caused by diet, restoring NAD+ improves metabolic measures in study after study. Active SIRT1 speeds up fatty acid oxidation and holds back the making of fat cells. There is no human weight-loss data.

Heart and blood vessels

• Blood pressure with NR. The 2018 Martens trial, a crossover design, gave early evidence that NR may lower systolic blood pressure and stiffness of the aorta. These were secondary endpoints, and the trial was small [3].
• Heart function in animals. Restoring NAD+ improved how the heart worked in mice with models of heart failure, of ischemia-reperfusion injury, and of heart muscle disease caused by the drug doxorubicin. The proposed mechanism is that SIRT3 protects mitochondrial function in heart muscle cells [9].
• Vessel lining. In preclinical models, SIRT1 turned on by NAD+ improved the function of endothelial cells, which line blood vessels, and reduced inflammation in the vessels. This backs the hypothesis that falling NAD+ adds to the vessel problems of aging.
• The gap. No NAD+ precursor has been through a human trial that counted cardiovascular events such as heart attack, stroke or cardiovascular death.

Exercise and physical performance

• Old mice. In aged mice, NMN brought running capacity on a treadmill back to a level close to that of younger animals. This came with better mitochondrial function and with skeletal muscle that oxidized more fatty acids [9].
• People. In the Uthever trial, NMN gave modest gains on the 6-minute walk test [4]. Other small studies have reported better aerobic capacity and grip strength. Their sample sizes are still small.
• The “exercise mimetic” debate. In preclinical models, NAD+ precursors have been called “exercise mimetics”. They turn on some of the pathways that exercise does: AMPK, SIRT1 and PGC-1α. In humans, it is still an open question whether they add to the body’s adaptation to exercise, stand in for it, or possibly get in its way.

NMN, NR and niacin compared

NAD+ is poorly absorbed when taken by mouth. The molecule is large and charged, and it does not cross cell membranes easily. So most research, and most supplement approaches, use precursors. These are smaller molecules that cells convert into NAD+ along known pathways. Three matter most: niacin, NR and NMN.

NMN

NMN stands for nicotinamide mononucleotide. It is a nucleotide built from three parts: a phosphate group, a ribose sugar and nicotinamide. A single enzyme step turns it into NAD+. The enzyme is NMNAT, short for nicotinamide mononucleotide adenylyltransferase. That makes NMN the precursor closest to NAD+ in the salvage pathway, the route by which cells recycle NAD+.

• Human trials. The number of clinical trials has grown since 2021. They include Yoshino’s trial of insulin sensitivity (10 weeks, 250 mg) [2] and the multicenter Uthever study (60 days, 600 mg a day) [4].
• Raising NAD+. Shown in blood and in tissues in animal models. The Uthever trial confirmed a rise in human blood NAD+.
• Main strength. It is one enzyme step from NAD+. It also occurs naturally, in trace amounts, in foods such as edamame, broccoli and avocado.
• Main weakness. It has less long-term safety data than NR. Its regulatory status is uncertain in some places. In 2022 the FDA issued a letter that questioned whether NMN counts, in the United States, as a dietary supplement.
• Getting into cells. How NMN enters cells was debated until 2019. That year scientists identified a transporter, Slc12a8, in the gut of mice. It has not been established that this transporter sets the pace in humans.

NR

NR, or nicotinamide riboside, belongs to the pyridine nucleosides. In essence it is nicotinamide joined to a ribose sugar, with no phosphate group. It gets into cells through nucleoside transporters (ENTs). NR kinases (NRK1 and NRK2) then add a phosphate to make NMN, and NMNAT turns that into NAD+. So NR is two enzyme steps away from NAD+.

• Human trials. Among the precursors, NR’s clinical evidence is the more established. Key studies include Martens and colleagues (2018, 1000 mg a day, 6-week crossover) [3], plus several follow-up trials that run through 2025.
• Raising NAD+. At 1000 mg a day, blood NAD+ rises about 60%. A 2024 crossover study from Norway suggested NR may raise blood NAD+ about 2.3 times more than NMN does when doses are equivalent. Only one comparison shows this [10].
• Main strength. A broader base of clinical evidence. Its uptake through nucleoside transporters is well described. Patent-protected versions (Niagen/TruNiagen) are made to consistent standards.
• Main weakness. Patent protection limits who can sell it and raises the cost. It takes two enzyme steps to reach NAD+, not one.

Niacin

Niacin, also called nicotinic acid, is vitamin B3. It is the oldest NAD+ precursor and the one studied most. Doctors have used it for decades to prevent pellagra and to manage blood lipids. It becomes NAD+ by the Preiss-Handler pathway. This route has several enzyme steps and passes through two middle forms: NaMN (nicotinic acid mononucleotide) and NaAD+ (nicotinic acid adenine dinucleotide).

• Human data. Clinical experience goes back decades. Its safety at therapeutic doses, 1 to 3 g a day for lipid management, is firmly established.
• Raising NAD+. It raises NAD+, but there is little data on it from anti-aging research in particular.
• Main strength. Cheap, easy to find, and its pharmacology is well described.
• Main weakness. It causes flushing, a reddening of the skin driven by prostaglandins after niacin binds the GPR109A receptor. This limits how well people tolerate effective doses. Few studies have looked at it for longevity endpoints.

Point	NMN	NR	Niacin
Enzyme steps to reach NAD+	One step (NMN → NAD+)	Two steps (NR → NMN → NAD+)	Several (Preiss-Handler pathway)
Human randomized trials	Growing (2021 to 2025)	More established (2018 to 2025)	Decades, for blood lipids
Rise in blood NAD+	Confirmed	About 60% at 1000 mg a day	Confirmed, with little aging data
Main strength	Nearest to NAD+ in the salvage pathway	Widest clinical evidence	Cheap and well described
Main weakness	Less long-term data, and regulatory questions	Under patent, and costs more	Flushing, and not studied for longevity
Direct comparisons	Few. One crossover study from Norway (2024) favored NR for raising blood NAD+ at equivalent doses [10]

Keep in mind: NMN has not been shown to lengthen human life, and neither has NR. The reported timeline goes like this. Blood NAD+ typically rises within 1 to 2 weeks of supplementation. People have reported feeling more energy over 4 to 8 weeks. Metabolic changes that can be measured, like better insulin sensitivity, have been recorded at 10 weeks [2].

Safety

In human trials

In published clinical trials, NAD+ precursors have looked generally safe over the short term.

• NMN, 250 to 600 mg a day. Tolerated well in trials that ran as long as 12 weeks, with no serious adverse events reported. Uthever, at 600 mg a day, found the safety profile acceptable, with no clinically significant shifts in lab values [4].
• NR, 1000 to 2000 mg a day. Tolerated well in the crossover trial by Martens, with no serious adverse events. Some people on higher doses reported mild side effects that passed: flushing, nausea and headache [3].
• Niacin. Its safety record at drug-level doses is long and firm. The main side effect is prostaglandin-driven flushing, which can be significant above 500 mg.

In animals

• Rodent studies found no organ damage at standard supplement doses.
• Mice given NMN for 12 months showed no obvious toxicity (Mills and colleagues, 2016) [12].
• Standard preclinical safety tests reported no damage to genes and no mutations.

What is not known

• Cancer risk. All fast-dividing cells run on NAD+, and cancer cells are among them. In theory, a supplement could feed the growth of a tumor that exists but has not been diagnosed. Nothing published so far gives clinical evidence of a higher cancer risk. Scientists are still actively studying it. Some argue that restoring NAD+ also lowers inflammation and helps DNA repair, and that this may offset any push toward cell growth. The question is not resolved.
• Long-term safety. No NAD+ precursor has safety data over several years in the longevity setting.
• Drug interactions. Nobody has run formal interaction studies. In theory there could be interactions with chemotherapy drugs, which may depend on draining NAD+ to work, with immune-suppressing drugs, and with other drugs that act on metabolism.
• Dose and response. Nobody knows the best dose for supplementation over the long term. A higher dose does not always raise NAD+ in proportion. The dose-response curve may level off.
• Exercise. It is unresolved whether NAD+ precursors add to, or get in the way of, the adaptations exercise causes in humans.

Legal status in the US

• No approval as a treatment. The FDA has not approved any NAD+ precursor to treat or prevent any disease. The same is true of the EMA in Europe and the MHRA in the UK.
• NMN. In 2022 the FDA issued a letter that questioned whether NMN has dietary supplement status in the United States.
• NAD+ itself. It is sold as a supplement less often than its precursors, because the body absorbs it poorly.
• Sport. The World Anti-Doping Agency does not have NMN, NR or niacin on its Prohibited List at present. Many peptide compounds are on it.

Limits of the research

1. Lifespan results come from animals only. Every result showing longer life comes from worms, yeast or mice. Human longevity has never been the primary endpoint of a randomized controlled trial. Better markers and better physical performance in people do not have to mean a longer life.
2. Blood may not match tissue. NAD+ in blood may not reflect NAD+ in tissues accurately. In Yoshino’s 2021 trial, NMN brought metabolic gains in skeletal muscle with no detectable change in whole-blood NAD+ [2]. So a study that uses only blood NAD+ as its primary outcome may understate or misstate what supplementation does in the body.
3. Short trials. Most human trials run 6 to 12 weeks. Aging is measured in decades. Nobody knows if short-term gains in markers last, or if they turn into long-term benefit.
4. Best dose unknown. There is no agreement on the best dose, how often to give it, or which precursor to pick among NMN, NR and niacin. Direct comparisons are still rare. People may also differ a lot in how they process NAD+.
5. Cancer question open. The theoretical worry that NAD+ supplements could help existing cancers grow has not been confirmed. It has not been firmly ruled out either. The gap matters most for older people, the very group most likely to gain from restoring NAD+.
6. Exercise overlap unclear. NAD+ precursors and exercise switch on some shared molecular pathways: AMPK, SIRT1 and PGC-1α. Whether precursors add to exercise adaptations in humans, partly replace them or interfere with them is an important open question.
7. CD38 inhibitor pairing untested. If CD38 is the main cause of falling NAD+, then a precursor plus a CD38 inhibitor (for example apigenin or quercetin) may work better than a precursor on its own. This combined strategy has no clinical evidence behind it yet.

The biology of NAD+ is settled, and small human trials show it can be raised. No study has yet shown that raising it helps people live longer or stay free of disease.

References

Selected peer-reviewed references. Ordered by relevance to guide sections.

1. Camacho-Pereira J, Tarragó MG, Chini CCS, et al. (2016). CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. Cell Metabolism, 23(6), 1127–1139. PMID: 27304511
2. Yoshino M, Yoshino J, Kayser BD, et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science, 372(6547), 1224–1229. PMID: 33888596
3. Martens CR, Denman BA, Mazzo MR, et al. (2018). Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications, 9, 1286. PMID: 29599478
4. Huang H, et al. (2022). A Multicentre, Randomised, Double Blind, Parallel Design, Placebo Controlled Study to Evaluate the Efficacy and Safety of Uthever (NMN Supplement), an Orally Administered Supplementation in Middle Aged and Older Adults. Frontiers in Aging, 3, 851698. PMID: 35821806
5. Hou Y, Lautrup S, Cordonnier S, et al. (2018). NAD+ supplementation normalizes key Alzheimer’s features and DNA damage responses in a new AD mouse model. Proceedings of the National Academy of Sciences, 115(8), E1876–E1885. PMID: 29432159
6. Chini EN, Chini CCS, Espindola Netto JM, et al. (2018). The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging. Trends in Pharmacological Sciences, 39(4), 424–436. PMID: 29482842
7. Imai S, Guarente L. (2014). NAD+ and Sirtuins in Aging and Disease. Trends in Cell Biology, 24(8), 464–471. PMID: 24786309
8. Verdin E. (2015). NAD+ in aging, metabolism, and neurodegeneration. Science, 350(6265), 1208–1213. PMID: 26785480
9. Rajman L, Chwalek K, Sinclair DA. (2018). Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. Cell Metabolism, 27(3), 529–547. PMID: 29514064
10. Yang Y, et al. (2025). An Updated Review on the Mechanisms, Pre-Clinical and Clinical Comparisons of Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR). Food Frontiers. DOI: 10.1002/fft2.511
11. Yusri K, Jose S, Vermeulen KS, Tan TCM, Sorrentino V. (2025). The role of NAD+ metabolism and its modulation of mitochondria in aging and disease. npj Metabolic Health and Disease, 3, 23. DOI: 10.1038/s44324-025-00067-0
12. Mills KF, Yoshida S, Stein LR, et al. (2016). Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. Cell Metabolism, 24(6), 795–806. PMID: 28068222